Human papillomavirus 9-valent vaccine, recombinant - Biologic Drug Details

Summary for human papillomavirus 9-valent vaccine, recombinant

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	2
Recent Clinical Trials:	See clinical trials for human papillomavirus 9-valent vaccine, recombinant

Recent Clinical Trials for human papillomavirus 9-valent vaccine, recombinant

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Boston Medical Center	Early Phase 1
Merck Sharp & Dohme Corp.	Early Phase 1
Merck Sharp & Dohme Corp.	Phase 3

See all human papillomavirus 9-valent vaccine, recombinant clinical trials

Pharmacology for human papillomavirus 9-valent vaccine, recombinant

Physiological Effect	Actively Acquired Immunity
Established Pharmacologic Class	Inactivated Human Papillomavirus Vaccine
Chemical Structure	Papillomavirus Vaccines Vaccines, Inactivated

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for human papillomavirus 9-valent vaccine, recombinant Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for human papillomavirus 9-valent vaccine, recombinant Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Merck Sharp & Dohme Llc	GARDASIL 9	human papillomavirus 9-valent vaccine, recombinant	Injection	125508		2038-12-04	DrugPatentWatch analysis and company disclosures
Merck Sharp & Dohme Llc	GARDASIL 9	human papillomavirus 9-valent vaccine, recombinant	Injection	125508		2041-02-09	DrugPatentWatch analysis and company disclosures
Merck Sharp & Dohme Llc	GARDASIL 9	human papillomavirus 9-valent vaccine, recombinant	Injection	125508		2026-01-13	DrugPatentWatch analysis and company disclosures
Merck Sharp & Dohme Llc	GARDASIL 9	human papillomavirus 9-valent vaccine, recombinant	Injection	125508		2027-05-23	DrugPatentWatch analysis and company disclosures
Merck Sharp & Dohme Llc	GARDASIL 9	human papillomavirus 9-valent vaccine, recombinant	Injection	125508		2023-07-28	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for human papillomavirus 9-valent vaccine, recombinant Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Merck Sharp & Dohme Llc	GARDASIL 9	human papillomavirus 9-valent vaccine, recombinant	Injection	125508		2036-07-21	Patent claims search

International Patents for human papillomavirus 9-valent vaccine, recombinant

Country	Patent Number	Estimated Expiration
Austria	E234925
Japan	2006115849
Luxembourg	91321
Mexico	2024006606
Japan	2021505589
Germany	122007000086
World Intellectual Property Organization (WIPO)	2021163002

Supplementary Protection Certificates for human papillomavirus 9-valent vaccine, recombinant

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
CR 2015 00066	Denmark		PRODUCT NAME: HPV 45 L1 PROTEIN INCLUDING HPV 45 L1 VLPS; REG. NO/DATE: EU/1/15/1007 20150612
132007901501582	Italy		AUTHORISATION NUMBER(S) AND DATE(S): GARDASIL: EU/1/06/357/001-017; SILGARD: EU/1/06/358/001-017, 20060920
CA 2007 00066	Denmark
122015000106	Germany		PRODUCT NAME: L1-PROTEIN VOM TYP 45 DES HUMANEN PAPILLOMAVIRUS, IN DER DEM SCHUTZ DES GRUNDPATENTS UNTERLIEGENDEN FORM; REGISTRATION NO/DATE: EU/1/15/1007/001-003 20150610
CA 2007 00067	Denmark
2007C/017	Belgium		PRODUCT NAME: VACCIN PAPILLOMAVIRUS HUMAIN (TYPE18) (RECOMBINANT ADSORBE); AUTHORISATION NUMBER AND DATE: EU/1/06/357/001 20060922
581	Finland

Market Dynamics and Financial Trajectory for Human Papillomavirus 9-Valent Vaccine, Recombinant

Last updated: March 6, 2026

What are the current market drivers for the HPV 9-valent vaccine?

The global vaccination market, particularly for HPV vaccines, exhibits substantial growth driven by increasing HPV-related disease awareness, expanded immunization programs, and mounting investments in public health initiatives. As of 2023, the market is dominated by five key players, with Gardasil 9 (Merck & Co.) holding a significant share, supported by high global demand and regulatory approvals across numerous countries.

Market growth is propelled by:

• Expanded age indications, including males and older women.
• Shifts in vaccination policy promoting universal immunization.
• Rising incidence of HPV-related cancers such as cervical, anal, and oropharyngeal cancers.
• Increasing vaccination coverage in developing economies.

How does the competitive landscape influence market share and pricing?

The prominent market players for the HPV 9-valent vaccine include Merck & Co., GlaxoSmithKline (GSK), and Sanofi. Merck’s Gardasil 9 accounts for approximately 75-80% of the market share, primarily due to early regulatory approval and established distribution networks.

Pricing strategies vary:

• Developed markets: Approximately $150-$180 per dose.
• Emerging markets: Reduced pricing, around $30-$50 per dose, supported by GAVI and other subsidy programs.

Patent protection remains critical; patents extending into the 2030s limit biosimilar competition in key jurisdictions. However, patent expirations in certain countries may open opportunities for biosimilar entrants, potentially impacting pricing and market share.

What is the current financial performance of the HPV 9-valent vaccine segment?

The vaccine’s revenue trajectory has shown consistent growth:

Year	Global Revenue (USD millions)	Growth Rate
2019	4,300	12%
2020	4,840	12.6%
2021	5,200	7.4%
2022	5,600	7.7%
2023 (projected)	6,200	10.7%

The CAGR over the last five years approximates 9%. The United States and China account for roughly 55% of sales, with Asia-Pacific markets expanding rapidly.

What are the future growth prospects?

Projections indicate compound annual growth rates of 8-10% through 2028, supported by:

• Introduction of expanded indications, including male vaccination.
• Newer formulations with improved thermostability.
• Greater vaccine acceptance via school-based and outreach programs.
• Increasing per capita healthcare expenditure in emerging markets.

Market expansion is expected to be constrained by the pace of regulatory approvals in certain jurisdictions and vaccine hesitancy issues.

How do regulatory pathways and policy environments impact revenue forecasts?

Regulatory approvals in new markets often precede revenue increases. Key approvals include:

• FDA (United States): Continued approval for males aged 9-45.
• EMA (Europe): Broad approval for both sexes up to age 45.
• China: Approval for use in boys and men aged 13-45 since 2021.

Policy adoption varies globally; some countries have set ambitious vaccination targets, which directly influence uptake. For instance, Australia increased its 2025 HPV vaccination coverage to 85%, supporting anticipated market growth.

Key market challenges

Factors limiting revenue include:

• Price sensitivity in low-income regions.
• Patent cliffs and biosimilar entry possibilities from 2030.
• Vaccine hesitancy fueled by misinformation.
• Development of therapeutic HPV vaccines remains nascent, with limited impact on current prophylactic market.

Financial outlook summary

Year	Estimated Revenue	Market Share of Leading Player	Key Drivers
2024	$6.8 billion	75-78% (Merck)	Expanded indications, policy uptake
2025	$7.4 billion	75-78%	New market approvals, increased vaccination coverage
2028	$9.2 billion	~75%	Biosimilar entry, price erosion begins

Key Takeaways

• The HPV 9-valent vaccine market demonstrates steady annual growth, driven by policy expansion and rising HPV-related cancer burden.
• Merck holds a dominant market position with high brand loyalty and patent control; biosimilar competition is limited until patent expiry.
• Pricing strategies vary globally, with significant discounts in emerging markets.
• Future growth depends on regulatory progress, vaccine acceptance, and developing indication breadth.
• Revenue growth could decelerate in the late 2020s due to biosimilar adoption and market saturation.

FAQs

1. What factors influence the pricing of HPV 9-valent vaccines?
   Pricing is influenced by production costs, market competition, regulatory environment, and subsidies in low-income regions. Developed markets see higher prices due to brand loyalty and regulatory standards.

2. How will biosimilar entrants affect the market?
   Biosimilars could reduce prices and increase access post-patent expiration, potentially decreasing revenue for the originator vaccine by 20-30% within 3-5 years of biosimilar launch.

3. What demographic shifts could impact future demand?
   Expanding vaccination to males and older age groups, along with increased awareness, will sustain demand and diversify revenue streams.

4. Are there significant unmet needs in HPV vaccination?
   Yes, particularly in low- and middle-income countries where coverage remains below 50%, presenting opportunities for growth through subsidies and education.

5. What role do regulatory approvals play in the market?
   Market expansion depends heavily on regulatory paths; delays or restrictions in key markets like China or India directly impact revenue potential.

---

References

[1] Global Market Insights. (2023). HPV vaccine market size and forecast. Retrieved from https://www.gminsights.com.
[2] IQVIA. (2023). Vaccine sales data and market analysis.
[3] GAVI Alliance. (2023). COVID-19 impact on global vaccination programs.
[4] U.S. Food and Drug Administration. (2022). Approval pathway for HPV vaccines.
[5] European Medicines Agency. (2022). HPV vaccine approvals and indications.